Emerging role of carbonic anhydrase inhibitors

被引:145
|
作者
Supuran, Claudiu T. [1 ]
机构
[1] Univ Florence, Neurofarba Dept, Pharmaceut & Nutraceut Sect, Via Ugo Schiff 6, I-500195 Florence, Italy
关键词
TARGETING TUMOR HYPOXIA; RAY CRYSTAL-STRUCTURES; ISOZYME-II; IN-VIVO; PHOSPHATASE-ACTIVITY; NEUROPATHIC PAIN; WATER-MOLECULES; PH REGULATION; ACTIVE-SITE; DRUG DESIGN;
D O I
10.1042/CS20210040
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) was clinically exploited for decades, as most modern diuretics were obtained considering as lead molecule acetazolamide, the prototypical CA inhibitor (CAI). The discovery and characterization of multiple human CA (hCA) isoforms, 15 of which being known today, led to new applications of their inhibitors. They include widely clinically used antiglaucoma, antiepileptic and antiobesity agents, antitumor drugs in clinical development, as well as drugs for the management of acute mountain sickness and idiopathic intracranial hypertension (IIH). Emerging roles of several CA isoforms in areas not generally connected to these enzymes were recently documented, such as in neuropathic pain, cerebral ischemia, rheumatoid arthritis, oxidative stress and Alzheimer's disease. Proof-of-concept studies thus emerged by using isoform-selective inhibitors, which may lead to new clinical applications in such areas. Relevant preclinical models are available for these pathologies due to the availability of isoform-selective CAIs for all human isoforms, belonging to novel classes of compounds, such as coumarins, sulfocoumarins, dithiocarbamates, benzoxaboroles, apart the classical sulfonamide inhibitors. The inhibition of CAs from pathogenic bacteria, fungi, protozoans or nematodes started recently to be considered for obtaining anti-infectives with a new mechanism of action. Carbonic anhydrase (CA, EC 4.2.1.1) was discovered in 1933 by Meldrum and Roughton [1] during experiments on the transport of CO2/bicarbonate in the blood, being noted that the large amounts of metabolically generated CO2 and its relatively low hydration rate at the physiological pH, implicated that an efficient catalyst must interconvert the two species [1,2]. This catalyst was indeed demonstrated to be a metalloenzyme, subsequently denominated by the two researches CA. Krebs and Roughton [3] later defined it as a 'tool in studying the mechanism of reactions involving H2CO3, CO2 or HCO3', which is role that this enzyme still has today after thousands of valuable studies that have been performed worldwide. Furthermore, it has been ascertained that in humans, as in most vertebrates, at least 15 different CA isoforms belonging to the alpha-class are widespread in many organs, tissues and cells, being involved in a multitude
引用
收藏
页码:1233 / 1249
页数:17
相关论文
共 50 条
  • [1] Multi- and polypharmacology of carbonic anhydrase inhibitors
    Supuran, Claudiu T.
    PHARMACOLOGICAL REVIEWS, 2025, 77 (01)
  • [2] Carbonic anhydrase inhibitors
    Supuran, Claudiu T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3467 - 3474
  • [3] Sulfonamides and their isosters as carbonic anhydrase inhibitors
    Carta, Fabrizio
    Supuran, Claudiu T.
    Scozzafava, Andrea
    FUTURE MEDICINAL CHEMISTRY, 2014, 6 (10) : 1149 - 1165
  • [4] An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors
    Supuran, Claudiu T.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (04) : 297 - 307
  • [5] Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas
    Supuran, Claudiu T.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (10) : 709 - 712
  • [6] Carbonic anhydrase inhibitors and activators for novel therapeutic applications
    Supuran, Claudiu T.
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (09) : 1165 - 1180
  • [7] Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment
    Angeli, Andrea
    Carta, Fabrizio
    Nocentini, Alessio
    Winum, Jean-Yves
    Zalubovskis, Raivis
    Akdemir, Atilla
    Onnis, Valentina
    Eldehna, Wagdy M.
    Capasso, Clemente
    De Simone, Giuseppina
    Monti, Simona Maria
    Carradori, Simone
    Donald, William A.
    Dedhar, Shoukat
    Supuran, Claudiu T.
    METABOLITES, 2020, 10 (10) : 1 - 21
  • [8] (In)organic anions as carbonic anhydrase inhibitors
    De Simone, Giuseppina
    Supuran, Claudiu T.
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 111 : 117 - 129
  • [9] Therapeutic Applications of Glycosidic Carbonic Anhydrase Inhibitors
    Winum, Jean-Yves
    Poulsen, Sally-Ann
    Supuran, Claudiu T.
    MEDICINAL RESEARCH REVIEWS, 2009, 29 (03) : 419 - 435
  • [10] Carbonic anhydrase inhibitors:: The β-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors
    Nishimori, Isao
    Minakuchi, Tomoko
    Kohsaki, Takuhiro
    Onishi, Saburo
    Takeuchi, Hiroaki
    Vullo, Daniela
    Scozzafava, Andrea
    Supuran, Claudiu T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (13) : 3585 - 3594